Communiqués Hemab Therapeutics Holdings, Inc.

Actions

Marché Fermé - Nasdaq 22:00:00 14/08/2026			Varia. 5j.	Varia. 1 janv.
54,94 ^USD	+1,84%		+10,63%	-

11/08	Hemab Therapeutics Holdings, Inc. : Wedbush reste à l'achat	ZM
11/08	Hemab Therapeutics : réduction de la perte nette au deuxième trimestre	MT

11/08	Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	GL
14/07	Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress	GL
12/07	Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress	GL
10/07	Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress	AQ
26/06	Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress	GL
27/05	Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference	GL
27/05	Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference	AQ
21/05	Hemab Therapeutics Reports First Quarter 2026 Financial Results	GL
04/05	Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	GL